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ABSTRACT
Head and neck cell squamous-cell carcinomas (HNSCC) are a group of common
cancers typically associated with tobacco use and human papilloma virus infection. Up to
half of all cases will suffer a recurrence after primary treatment. As such, new therapies
are needed, including therapies which promote the anti-tumor immune response. Prior
work has characterized changes in the mutation burden between primary and recurrent
tumors; however, little work has characterized the changes in neoantigen evolution. We
characterized genomic and neoantigen changes between 23 paired primary and recurrent
HNSCC tumors. Twenty-three biopsies from patients originally diagnosed with locally
advanced disease were identified from the Washington University tumor bank. Whole
exosome sequencing, RNA-seq, and immunohistochemistry was performed on the primary
and recurrent tumors. Within these tumors, we identified 6 genes which have predicted
neoantigens in 4 or more patients. Interestingly, patients with neoantigens in these shared
genes had increased CD3+ CD8+ T cell infiltration and duration of survival with disease.
Within HNSCC tumors examined here, there are neoantigens in shared genes by a subset
of patients. The presence of neoantigens in these shared genes may promote an anti-tumor
immune response which controls tumor progression.

INTRODUCTION

and chemotherapy [3]. Although these treatments may lead
to cure, relapse of disease occurs in 30–50% of patients
[4, 5].
Current therapies for relapsed or metastatic HNSCC
include immunotherapy, chemotherapy, or cetuximab [6].
Immunotherapy was shown to prolong overall survival
in comparison to chemotherapy given with or without
cetuximab [7–10]. A relatively new FDA-approved type
of therapy for HNSCC are immune checkpoint inhibitors.
Immune checkpoint molecules, such as PD-1, PD-L1, and
CTLA-4, are surface molecules on the surface of activated

Head and neck cancer are a group of heterogeneous
tumors with an estimated 644,000 new cases per year
worldwide [1]. Head and neck cancers represent 3%
of all new cancer cases and 2% of all cancer-related
deaths. Most head and neck cancers have squamouscell carcinoma morphology (HNSCC). Risk factors for
HNSCC include tobacco use and human papilloma virus
(HPV) infection [2]. In locally advanced disease, current
therapies include combinations of resection, radiotherapy,
www.oncotarget.com
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immune cells [11]. The binding of PD-1 to PD-L1 or
CTLA-4 to CD80/CD86 inhibits the immune response. By
blocking the binding of these checkpoint molecules, the
immune response against the tumor is licensed to continue.
The efficacy of checkpoint inhibitors in HNSCC
indicates a role for the immune system in the control and
elimination of this disease. The infiltration of immune
cells, including T cells, into tumor is associated with
improved outcomes and longer survival in HNSCC [12–
17]. The infiltrating T cells release granules containing
perforin and granzyme A and B which directly kill tumor
cells or release other cytokines and chemokines that
promote the anti-tumor immune response and alter the
tumor microenvironment [18]. For example, infiltrating T
cells release interferon gamma which increases expression
of PD-L1 and CTLA-4, which may increase the efficacy
of immune checkpoint therapy [19, 20].
During the progression of cancer, there is an
increased mutational burden. These mutations can result in
the development of neoantigens. These neoantigens may
mark some clones for immunoediting and elimination.
However, the clones which escape immunoediting are the
source of cancer cell persistence, relapse, and metastasis.
Multiple studies have characterized changes in mutation
burden in HNSCC [21–24], when comparing primary
and metastatic tumors, no studies have characterized the
shifting neoantigen burden between primary and metastatic
tumors within HNSCC. In this study, we characterized the
mutational and neoantigen burden between primary and
first recurrence tumors in 23 patients with HNSCC. In this
analysis, primary and recurrent tumors were identified
that had neoantigens in shared genes in multiple patients.
These patients had increased CD8+ cell infiltration and
increased expression of cytolytic gene expression. This
study provides the justification for looking at a larger
dataset in a prospective manner for the identification of
recurrent neoantigens in the evolution of HNSCC.

[25]. In our patient population, 20 of the 23 patients (87%)
received radiation, 13 of 23 (57%) received cisplatin, 7 of
the 23 patients (30%) received no chemotherapy, and 3 of
23 patients (13%) received Cetuximab (Table 2).

Sequencing data and bioinformatics workflow
Of the 23 patients, we sequenced 23 blood samples
for germline WES data and 46 paired primary and
recurrent/metastatic samples from paraffin blocks to
generate WES data, and performed RNA-Seq successfully
for 31 samples (Figure 1 and Methods). Next, we
generated clean data for downstream analysis based on a
standard pipeline. To call high confidant mutations from
46 paired tumor-germline WES data, we used four somatic
mutation tools to call mutations and filtered false-positive
mutations via bam-readcount tool. Of the RNA-Seq
data, for 16 primary tumors and 15 recurrent/metastatic
tumors gene expression was predicted using kallisto [26]
(Figure 1). To predict neoantigens, we utilized OptiType
[27] and MuPeXI [28] to define candidate neoantigens for
46 tumor samples.

Comparison of somatic mutations between
primary and recurrent/metastatic
Based on the WES, total somatic mutations were
identified for each of the patients. Patients were sorted
by patients with the highest neoantigen burden. Patients
H004, H003, H002, H008, H011, H018, and H014 have
the greatest number of total somatic mutations compared
with other patients (Figure 2A). Interestingly, three of
the patients have a primary tumor in the larynx (Patients
H004, H003, and H011) and 3 patients (H008, H018, and
H014) have a primary tumor in the oropharynx. There is
a general trend that the recurrent/metastatic tumor has
more mutations than the primary tumor (Figure 2A). The
majority of all somatic mutations are missense mutations
and silent mutations. To understand the recurrent mutation
effect between primary and recurrent/metastatic tumors,
we extract recurrently mutated genes (>1 sample mutated
gene) from primary and recurrent/metastatic samples,
separately. We detected 536 and 786 recurrently mutated
genes from primary and recurrent/metastatic samples,
respectively (Figure 2B). Of them, 319 genes shared both
of primary and recurrent/metastatic tumors.
We next performed KEGG pathways (http://www.
webgestalt.org) analysis to determine if somatic mutations
were in pathways related to metastasis. Of them, most of
the significant gene enrichment pathways tend toward the
relapse due to the generally higher number of mutations in
the recurrent/metastatic compared to the primary samples
(Figure 2B). Of them, ABC transporters, Adherens
junction, cAMP signaling, and Taste transduction
pathways were significant only in recurrent/metastatic
samples, and extracellular matrix (ECM)-receptor

RESULTS
Patient demographics
Twenty-three HNSCC patients were identified
that were consented to the Washington University tumor
bank and had genetic material available for germline,
primary tumor and first recurrence/metastases (patient
characteristics are listed in Table 1). Males represented 17
of 23 patients (74%) of the patient population. Tobacco
smokers represented 14/23 (61%), 7 (30%) patients were
non-smokers, 1 (4%) patient chewed tobacco and 1 (4%)
patient smoked marijuana. Primary tumors are in the
oral cavity (9/23, 39%), oropharynx (7/23, 30%), larynx
(6/23, 26%), and hypopharynx (1/23, 4%). All seven
oropharyngeal patients (7/23, 30%) were positive for the
human papilloma virus (HPV+). All of these percentages
are similar to those reported in the cancer genome atlas
www.oncotarget.com
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interaction, Human papillomavirus infection, and PI3KAkt signaling pathways were significant in both of
primary and recurrent/metastatic samples. Notably, ECMreceptor interaction pathway was extremely significant in
recurrent/metastatic samples meaning that genes related to
this pathway are more highly mutated than other pathway
mutations in recurrent/metastatic samples. ECM–receptor
interaction signaling pathway plays a crucial role in
modulating breast cancer metastases [29, 30]. We then
checked driver gene inflection for primary and recurrent/
metastatic samples via 299 known driver genes [31].
Figure 2C demonstrates the high frequency of mutations in
the top 20 driver genes. TP53 gene is the highest mutated
driver gene in both sample groups. We further identified
differential mutations in the driver genes between the
primary and recurrent/metastatic tumors. In doing so,
we identified that BRCA1 and NOTCH1 driver genes
are highly mutated in primary samples, and PIK3CA,
ARID1A, RASA1, TSC2, and ERBB4 were mutated higher
in recurrent/metastatic compared with primary samples.
Especially, CIC, KIF1A, LATS1, RARA, SPTAN1 genes
only mutated in recurrent/metastatic samples (Figure 2D).

difference in the infiltration of CD3+ cells (Figure 3A),
activated T cells (CD3+ HLA-DR+) (Figure 3B), cytotoxic
T cells (CD3+ CD8+) (Figure 3C), or CD3+ FOXP3+ cells
(Figure 3D) between the primary and recurrent tumor.
IHC was also used to determine the surface expression of
PD-L1 on tumor cells. There was a significant increase in
the tumor expression of PD-L1 between the primary and
recurrent/metastatic tumors (Figure 3E).

Gene expression patterns for immune check
point genes
Eleven pairs of primary and recurrent/metastatic
tumors were further determined using Kallisto [26]. There
is a significant reduction in the expression of the antigen
presenting genes B2M, HLA-A, HLA-B, and HLA-C in the
recurrent/metastatic tumors relative to the primary tumors
(Figure 4). To confirm the immunohistochemistry results,
the expression of CD3E, HLA-DRA, CD8A, and FOXP3
was examined in the primary and recurrent/metastatic
tumors. There was a decrease in the expression of all four
of these genes in the recurrent/metastatic tumors, relative
to the primary tumors. Only HLA-DRA was significantly
decreased. Cytolytic (CTL) activity is the geometric
mean of the expression of perforin and granzyme A [32].
There was no change in the expression of CTL activity
between the primary and recurrent/metastatic tumors. The
expression of CD274 (gene for PD-L1) was significantly

Immune cell infiltration
To determine the infiltration of immune cells
into the primary and recurrent/metastatic tumors,
immunohistochemistry (IHC) was performed. There is no

Figure 1: Flowchart of patient samples. The blue circles are the samples where DNA was sequenced and analyzed, green circles are
the samples where immunohistochemistry was performed, and yellow are the samples where had RNA sequenced and analyzed.

www.oncotarget.com
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Table 1: Patient demographics
Anatomic site

P16_status

Smoking History

Gender

Stage

Patient ID

Oropharynx

Positive

15 Pack-years

Male

Stage IVB T4bN2cM0

001

Oropharynx

Positive

Marijuana 1 Pack-years

Male

Stage IVA T2N2bM0

007

Oropharynx

Positive

Non-smoker

Male

Stage IVA T2N2bM0

008

Oropharynx

Positive

45 Pack-years

Male

Stage IVA T4aN2bM0

014

Oropharynx

Positive

10 Pack-years

Male

Stage IVA T1N2bM0

017

Oropharynx

Positive

Non-smoker

Male

Stage IVA T3N2bM0

018

Oropharynx

Positive

Non-smoker

Male

Stage IVA T2N2bM0

021

Hypopharynx

Negative

45 Pack-years

Male

Stage IVA T2N2aM0

005

Larynx

Negative

70 Pack-years

Male

Stage IVA T3N2M0

003

Larynx

Negative

14 Pack-years

Male

Stage IVA T3N3M0

004

Larynx

Negative

Chew for 42 years

Male

Stage I T1N0M0

009

Larynx

Negative

50 Pack-years

Female

Stage IVA T3N2bM0

011

Larynx

Negative

33 Pack-years

Female

Stage III T3N1M0

019

Larynx

Negative

68 Pack-years

Male

Stage III T2N1M0

013

Oral cavity

Negative

38 Pack-years

Male

Stage IVA T3N2M0

002

Oral cavity

Negative

Non-smoker

Male

Stage IVA T2N2bM0

010

Oral cavity

Negative

70 Pack-years

Male

Stage IVA T4N2bM0

012

Oral cavity

Negative

50 Pack-years

Male

Stage III T3N1M0

016

Oral cavity

Negative

50 Pack-years

Male

Stage IVA T4N2cM0

020

Oral cavity

Negative

Non-smoker

Male

Stage III T2N1M0

024

Oral cavity

Negative

Non-smoker

Female

Stage IVA T2N2bM0

006

Oral cavity

Negative

15 Pack-years

Female

Stage III T2N1M0

015

Oral cavity

Negative

Non-smoker

Female

Stage III T3NXM0

023

increased in the recurrent/metastatic tumors relative to
the primary tumors, similar to the immunohistochemistry
results in Figure 3. Finally, the expression of the
checkpoint molecules PDCD1 (gene for PD-1) and CTLA4
were examined. There was a decrease in the expression of
both molecules, and PDCD1 was significantly decreased
(Figure 4).

the recurrent/metastatic tumor, there was a trend toward
more neoantigens in the recurrent/metastatic compared
to the primary tumors (Figure 5B). We next sought to
determine if genes containing neoantigens were shared
between patients. Most neoantigens were unique to an
individual tumor. While there were some genes containing
neoantigens that were shared between 2 or 3 patients, a
total of five genes with neoantigens were shared by 4 or 5
patients (Figure 5C). Of these genes, three (RYR3, DNAH7,
and TTN) were identified from the primary tumors. There
were three genes (PIK3CA, USH2A, and TTN) containing
neoantigens in the recurrent/metastatic tumors. A summary
of the number of predicted neoantigens from each of the
identified genes from each patient are listed in Table 3.
The amino acid sequence for the predicted neoantigen and
the predicted HLA presenting the neoantigen are listed in
Supplementary Table 1. It is important to note that while
the genes which share the neoantigens are shared between
patients, the predicted neoantigen peptides are unique to
each patient because the mutations varied between patients.
There is one peptide sequence shared between patients.
Both Patient 001 and 018 have a predicted neoantigen from

Landscape of HLA genotypes and neoantigens
HLA types for each patient were determined with
OptiType [27], and the most common HLA type was
HLA-A*02:01, which was present in almost half (11/23)
of patients (Figure 5A). Other common HLA types
include HLA-C*07:01 (9/23 patients), HLA-A*01:01
(7/23), and HLA-B*08:01 (7/23). Using the data from
somatic mutations and HLA genotypes, neoantigens were
predicted using MuPeXI [28]. Patients H004, H003, H002,
H008, H011, H018, and H014 had the highest neoantigen
burden (Figure 5B). These are the same patients who had
large numbers of somatic mutations in Figure 2A. While
there were specific neoantigens in either the primary or
www.oncotarget.com
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Table 2: Patient treatments
Genome ID

Anatomic site

Treatment Type

Chemotherapy

Radiation Therapy

HNSCC-001

Oropharynx

definitive

cisplatin

Yes

HNSCC-007

Oropharynx

post-operative

cisplatin

Yes

HNSCC-008a

Oropharynx

Surgery only

none

No

HNSCC-014

Oropharynx

post-operative

cisplatin

Yes

HNSCC-017

Oropharynx

post-operative

cisplatin

Yes

HNSCC-018

Oropharynx

post-operative

None

Yes

HNSCC-021

Oropharynx

post-operative

cisplatin

Yes

HNSCC-005b

Hypopharynx

Surgery only

None

No

HNSCC-003

Larynx

post-operative

None

Yes

HNSCC-004

Larynx

definitive

cisplatin

Yes

HNSCC-009

Larynx

definitive

None

Yes

HNSCC-011

Larynx

post-operative

Yes

HNSCC-019

Larynx

neoadjuvant

cisplatin
abraxane/5FU/cisplatin;
cisplatin with RT

HNSCC-013

Larynx

HNSCC-002
HNSCC-010

Oral Cavity
Oral Cavity

post-operative
post-operative
post-operative

cisplatin
taxol/cetuximab
cetuximab

Yes
Yes
Yes

HNSCC-012c

Oral Cavity

Surgery only

None

No

HNSCC-016d

Oral Cavity

HNSCC-020
HNSCC-024
HNSCC-006
HNSCC-015
HNSCC-023

Oral Cavity
Oral Cavity
Oral Cavity
Oral Cavity
Oral Cavity

post-operative
post-operative
post-operative
post-operative
post-operative
post-operative

cisplatin
cisplatin
cisplatin
None
cisplatin
cetuximab

Yes
Yes
Yes
Yes
Yes
Yes

Yes

no adjuvant treatment given. b2nd primary for H&N. cdeveloped lung metastasis before adjuvant treatment could start. dpatient
stopped treatment early.
a

Neoantigens and CTL activation

533-542 of PIK3CA in their recurrent tumor. Both patients
have a mutation to lysine at position 542.
To determine if the predicted neoantigens were
a result of HLAs found in this patient population, we
looked at the distribution of the HLAs predicted to present
neoantigens from the shared genes (Figure 5D). A total of
14 of the 23 patients are represented in this group. Four
patients had neoantigens predicted in primary tumors
to be displayed on HLA-A*02:01, and two patients had
had neoantigens in the recurrent tumor displayed on this
haplotype. Three patients with mutations in recurrent
tumors were presented on HLA-B*08:01 and three
patients had primary tumor neoantigens predicted to be
displayed on HLA-B*07:02. These are on the only other
haplotypes utilized by more than 2 patients. This suggests
that the presence of neoantigens in these shared genes are
not a result of HLA distribution in this population.
www.oncotarget.com

We sought to determine the effect of these
neoantigens in shared genes on the patient. Patients with
neoantigens in these shared genes tend toward higher
overall neoantigen burden compared to those without
neoantigens in these shared genes (Figure 6A). In primary
tumors, patients with neoantigens in RYR3 and DNAH7
have significantly more total neoantigens compared to
patients without neoantigens in these shared genes. The
duration of survival with disease was also increased in
patients with these neoantigens in shared genes compared
to those without (Figure 6B). Without neoantigens in shared
genes, the mean duration of survival with disease is 1,200
days. There was a non-significant increase in the patients
with neoantigens in shared genes ranging from 1,382–2,052
days. This increase in the duration of survival with disease
538
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Table 3: Number of neoantigens in selected genes
Anatomic site

Patient
ID

RYR3
Primary

DNAH7
Primary

Oropharynx

001

Oropharynx

007

Oropharynx

008

Oropharynx

014

Oropharynx

017

Oropharynx

018

Oropharynx

021

Hypopharynx

005

Larynx

003

5

2

Larynx

004

9

1

Larynx

009

Larynx

011

Larynx

019

Larynx

013

Oral cavity

002

Oral cavity

010

Oral cavity

012

Oral cavity

016

Oral cavity

020

Oral cavity

024

Oral cavity

006

Oral cavity

015

Oral cavity

023

TTN
Primary

PIK3CA
Recurrent

USH2A
Recurrent

1
9
3

3
2

8
4

7

7

6

3

1

3

11

5

5

1
2

3
2
4

2
4

3

may be related to higher infiltration of CD3+ CD8+ cells
as determined by IHC (Figure 6C). In the primary tumor,
there are no significant changes in CD3+ CD8+ density. In
the recurrent/metastatic tumors, patients with neoantigens
in TTN, PIK3CA, and USH2A increased CD3+ CD8+
infiltration approximately 3-fold compared to patients
without neoantigens in these genes. The expression of
CD8A was increased in primary tumors with neoantigens in
RYR3 and DNAH7 and in recurrent/metastatic tumors with
neoantigens in TTN and PIK3CA (Figure 6D). CTL activity
trended to be increased in patients with the neoantigens in
RYR3 and DNAH7 in primary tumors and neoantigens in
TTN and PIK3CA in recurrent/metastatic tumors (Figure
6E). This is notable given there was no change in CTL
activity in between primary and recurrent/metastatic tumors
(Figure 4), but the sample size is small.

3
found an expected increase in the number of mutations
in the recurrent/metastatic tumors compared to the
primary tumors. By IHC, we found no differences in
the infiltration of immune cells, however the recurrent/
metastatic tumors had decreased expression of the antigen
presenting genes, B2M, HLA-A, HLA-B, HLA-C, and HLADR, and the checkpoint molecule PDCD1 and increased
CD274 expression compared to the primary tumors. Most
importantly, we identified neoantigens in the recurrent
genes in four-five patients. These patients have increased
total neoantigens, and a trend toward increased duration of
survival with disease, infiltration of CD8 cells, and CTL
activity. This suggests HNSCC neoantigens can stimulate
an anti-tumor immune response.
For the primary and recurrent/metastatic HNSCC
tumors, there is an increased mutational burden. It is
interesting that the number of mutations is not simply
increasing from the primary to the recurrent/metastatic
tumor, but they are changing, with the primary and
recurrent/metastatic tumors having unique sets of
mutations. While the change in mutational burden

DISCUSSION
In this study, we sequenced the primary and the
recurrent/metastatic tumor from 23 HNSCC patients and
www.oncotarget.com
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The expression of MHC I genes (B2M, HLA-A, HLA-B,
and HLA-C) were decreased significantly. This suggests
the ability to present antigens to the infiltrating immune
cells is decreased in the recurrent/metastatic compared to
the primary tumor. Despite this decrease in MHC I gene
expression, this does not correspond to changes in the T
cell infiltration. By IHC, there were no significant changes
in the infiltration of any examined T cell population
in primary and recurrent/metastatic tumors. This is

will have implications for the neoantigen burden, the
alteration of mutational burden will have impacts on
the biology of the tumor and on tumor metastasis. For
example, the upregulation of the PI3K can upregulate
matrix metalloproteins and upregulation of extracellular
matrix-receptor pathways are associated with metastasis
and invasion [21, 22, 24].
Next, we examined the infiltration of T cells into the
tumor with immunohistochemistry and gene expression.

Figure 2: Characterization of DNA sequences of primary and recurrent/metastatic tumors. (A) Based on DNA sequencing

of 23 paired primary and recurrent/metastatic tumors, the total number of somatic mutations for each patient primary and recurrent/
metastatic tumor. The different mutation types are indicated in different colors. (B) Based on the sequencing from all 23 paired primary and
recurrent/metastatic tumors, KEGG pathways was used to determine which pathways are enriched for mutations in either the primary or the
recurrent/metastatic tumor. The Venn Diagram is of the total number of recurrent mutations in the primary tumor alone, recurrent/metastatic
tumor alone, or shared. (C) The number of patients with mutations in the top 20 most frequently mutated driver genes in both the primary
and the recurrent/metastatic tumors. (D) Distribution of mutations in driver genes. In both the primary and recurrent/metastatic tumor, the
variant allele frequency is greater than 0.5 is indicated for each patient.
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consistent with the gene expression of CD3E which also is
unchanged between the primary and recurrent/metastatic
tumor. While the expression of HLA-DR on T cells is a
marker of activation [33, 34], the expression of HLA-DRA
is significantly reduced. HLA-DR is expressed from other
immune cells (such as antigen presenting cells), suggesting
the decreased expression of the total tumor is due to the
downregulation of HLA-DRA in other cells. Interestingly,
down-regulation of HLA-DRA is also associated with
non-activated antigen presenting cells.

Beyond the infiltration of the cells, CTL activity
(geometric mean of perforin and granzyme A expression)
is not noticeably different between the primary and the
recurrent/metastatic tumors. So, there is no change in
either the infiltration of CD3+ CD8+ cells or cytolytic
activity. Lastly, by immunohistochemistry, CD3+
FOXP3+ cells and by RNA-Seq, FOXP3 expression is not
significantly changed between the primary and recurrent/
metastatic tumor. This suggests that the infiltration of T
cells in general and more specifically cytotoxic T cells and

Figure 3: Immunohistochemistry of T cell infiltration into the tumor. Twenty paired blocks from the primary and relapse tumor

were stained for (A) CD3+ (cyan), (B) CD3+ (cyan) HLA-DR+ (orange), (C) CD3+ (cyan) CD8+ (magenta), (D) CD3+ (cyan) Foxp3+
(yellow), and (E) Tumor+ (Pan Cytokeratin red) PD-L1+ (green). All sections contain DAPI (blue). The density of the paired samples are
graphed. Significance was determined using a paired t test with. A p-value is significant if it is less than 0.05, ns = not significant. Images
are 20× magnification and the scale bar is 50 µm.
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CTLA4 are decreased in the recurrent/metastatic tumor
compared to the primary tumor. As has been previously
described, the expression of check point molecules, in
particular PD-L1, is important for determining the efficacy
of check point inhibition therapy [7, 8]. The observation
that the expression of these checkpoint molecules changes
between the primary and recurrent/metastatic tumors has
potential implications for therapeutic development. While
additional studies are needed, these results suggest that
changes to check point molecule expression may facilitate
the relapse of HNSCC.
It is not surprising that the patients with highest
numbers of total somatic mutations have the highest

Tregs are not different between the primary and recurrent/
metastatic tumors. However, we did not examine other
immune cell populations. More work is needed to further
determine the different immune populations within the
tumor. It would be interesting to determine the infiltration
of other immune cell populations and approximate the
activation state of these cells, but this would require a
larger data set.
We also tested the expression of check point
molecules by IHC and gene expression. PD-L1 is
significantly increased on tumor cells by IHC. This
increase is reflected by significantly increased expression
of CD274 in the tumor. Both PDCD1 (gene for PD-1) and

Figure 4: Expression of immune genes in the tumor. The expression of 11 paired primary and relapse tumors was determined by
the equation Log 2 (TPM of the indicated gene +1). CTL activity is the geometric mean for the expression of Granzyme A and Perforin.
Pri-primary tumor, Rec-Recurrent/metastatic tumor. Significance was determined using a paired t test with. A p-value is significant if it
is less than 0.05. *denoted p-value < 0.05 **denotes p-value < 0.01, ns = non-significant. The numbers under the X-axis are mean of gene
expression.
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neoantigen burden. As with somatic mutations, many
neoantigens are shared between the primary and recurrent/
metastatic tumor. However, there is a shifting neoantigen
burden as there are unique neoantigens in primary
tumors and different unique neoantigens in the recurrent/
metastatic tumors. Interestingly, there are neoantigens
in genes shared between up to five of the 23 patients.
The patients which have these neoantigens in shared
genes are patients which have higher total numbers of

neoantigens. As such, it is not clear if the differences
identified are due to the specific neoantigens or to the
increased total number of neoantigens. What is clear is
that patients with neoantigens in these shared genes also
tend to have increased duration of survival with disease.
The increased survival may not have been statistically
significant, but the increased survival for more than
100 days would be noticeable for the life of the patient.
While much more work is needed to expand on these

Figure 5: Neoantigen burden and evolution. (A) For the 23 patients for which there was DNA, the number of patients expressing
HLA-A, -B, and –C alleles in the patient population. (B) For 23 patients, the total number of neoantigens predicted in the primary tumor
alone (Blue), relapse tumor alone (Red), and shared (Gray). (C) The number of predicted neoantigens for each gene was graphed by the
number of patients sharing those neoantigens. (D) For the patients with neoantigens in shared genes, the number of patients with HLAs
predicted to present neoantigens. Neoantigens in primary tumors are in red, neoantigens in recurrent tumors are in blue.
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results, the observation that five patients in this relatively
small sample have neoantigens in the shared genes is
remarkable. The increase in neoantigens and duration of
survival with disease tends to be associated with increased
CD3+ CD8+ density in the tumor and CD8A expression.
More interestingly, there is a trend toward increased in
CTL activity in the patients with shared neoantigens. This

suggests that patients with these shared neoantigens are
associated with increased CD8+ T cell infiltration and
increased cytotoxic activity, which extends the patient’s
life. This raises the possibility that the presentation of
certain neoantigens are important for control of tumor
growth. This small exploratory study will provide the
justification for a larger study of neoantigens in HNSCC.

Figure 6: Properties of patients who have neoantigens in shared genes. (A) The total number of neoantigens was graphed for
primary tumors with neoantigens in Ryr3 (n = 4), DNAH7 (n = 5), TTN (n = 5), or no neoantigens (Pri neoAg-, (n = 13)) or relapse tumors
with neoantigens in TTN (n = 4), PIK3CA (n = 5), USH2A (n = 5), or no neoantigens (Rel neoAg-, (n = 12)). The numbers under the X
axis are the mean of neoantigens. *indicates p < 0.05. (B) The duration of disease for patients with predicted neoantigens in the Primary
tumor (Ryr3 (n = 4), DNAH7 (n = 5), TTN (n = 4)) and relapse tumor (TTN (n = 4), PIK3CA (n = 4), and USH2A (n = 5)), or no predicted
neoantigens in these genes (neoAg-, (n = 9)). Patients with neoantigens in multiple genes are placed in all neoantigens. The asterisks
indicate patients who were alive as of writing. (C) The density of CD3+ CD8+ cells in the tumor graphed by presence of neoantigens in
shared genes. Primary RYR3 (n = 4), Primary DNAH7 (n = 5), Primary TTN (n = 5), Primary no neoantigens (n = 11), relapse TTN (n =
4), relapse PIK3CA (n = 5), relapse USH2A (n = 5) relapse no neoantigens (n = 10)). Numbers under the X axis are the mean of the density.
(D) The Log2 (TPM +1) expression of CD8A was graphed by the presence of neoantigens in shared genes. Pri NeoAg- (n = 10), Pri Ryr3+
(n = 2), Pri DNAH7+ (n = 1), Pri TTN+ (n = 4), Rel neoAg- (n = 8), Rel TTN+ (n = 2), Rel PIK3CA+ (n = 5), Rel USH2A+ (n = 1). The
number under the X axis is the mean for each column. (E) The CTL activity was graphed by neoantigen status. CTL activity was calculated
as described in Figure 4. Pri NeoAg- (n = 10), Pri Ryr3+ (n = 2), Pri DNAH7+ (n = 1), Pri TTN+ (n = 3), Rel neoAg- (n = 8), Rel TTN+ (n
= 2), Rel PIK3CA+ (n = 5), Rel USH2A+ (n = 1). The number under the X axis is the mean for each column.
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MATERIALS AND METHODS

million (TPMs), gene expression was calculated by log
2 (TPM +1). Significance was determined using Prism
Graphpad (V8.4.3) using a paired two-tailed t test with
values determined to be significant when p-value < 0.05.

Patient identification
The HNSCC tumor bank at Washington University
was queried for patients that had consented for genomic
analysis IRB#201102323. To be included in this study,
tumor material had to be available from germline (white
blood cells), primary tumors and first recurrence/metastases.

Neoantigen prediction
HLA class I genotype was predicted from the WES
data using OptiType (v1.2.1) [27]. Combined with HLA
genotypes, non-synonymous mutations, and gene expression
profile, MHC class I specific binding neoantigens were
predicted using MuPeXI (v1.2.0) [28]. The binding affinity
of MHC class I with candidate peptides were evaluated with
netMHCpan-4.0 [40]. Candidate neoantigens were identified
as those with a predicted mutant peptide binding affinity of
< 500 nM for peptides of length 8–11 amino acids. After
that, the low gene expression (TPM < 0.5) neoantigens were
filtered, if the sample has RNA-Seq data. In addition, the
inner-duplicated short peptides and the peptides with the
same MHCaffinity values between normal and the tumor
columns were removed from each sample.

Sequenced data set and filtering
Of the 23 cases, a total of 69 samples (23 blood
samples (for germline), 23 primary tumors, and 23
recurrent/metastatic tumors) had DNA and total RNA
independently extracted, whole exome sequencing
(WES), and RNA-Seq (performed using NovaSeq 6000
sequencing system). Of the raw data, the WES data
included 23 blood normal samples, 23 primary tumors,
and 23 recurrent/metastatic tumor samples. RNA-Seq
raw data was available for 16 primary tumors and 15
recurrent/metastatic tumors. After that, adapter and lowquality sequences were trimmed from raw 2 × 150 bp
paired-end reads using Trim Galore (v0.5.0) (https://www.
bioinformatics.babraham.ac.uk/projects/trim_galore). The
resulting WES reads were then filtered for the duplicated
reads and converted to bam format for use in downstream
analysis. For the RNA-Seq, we used trimmed reads as the
input to downstream analysis.

Quantitative multiplex immunofluorescence
Six-marker multiplex immunofluorescence on 21
formalin-fixed paraffin embedded primary and recurrent/
metastatic tumors was performed using the PerkinElmer/
Akoya (Marlborough, MA) Opal reagents for multiplex
immunofluorescence with the following primary antibodies
CD3 (clone LN10, Leica #NCL-L-CD3-565), HLA-DR
(clone LN-3, Abcam #ab166777), CD8 (clone 4B11, Leica
#PA0183), FoxP3 (clone 236A-37, Abcam #ab20034),
panCK (clone PCK-26, Abcam #ab6401), and PD-L1 (clone
SP142, Abcam #ab228462), followed by image acquisition
on the PerkinElmer/Akoya Vectra 3 automated multispectral
microscope and data processing and analysis using the
PerkinElmer/Akoya inForm analysis software. The density
of CD3+, CD3+ HLA-DR+, CD3+ CD8+ CD3+ FOXP3+,
and Tumor+ PD-L1+ cells inside the primary and recurrent/
metastatic tumors was determined from the software and was
averaged for the primary and recurrent tumors. Significance
was determined using Prism Graphpad using a Wilcoxon
matched-pairs signed rank test with values determined to be
significant when p-value < 0.05.

Somatic variant calling
Somatic mutations were determined using
an in-house pipeline (https://github.com/ding-lab/
somaticwrapper) named as SomaticWrapper, which uses
several somatic variant calling tools including Strelka
(v2.9.2) [35], Mutect (v1.1.7) [36], VarScan (v2.3.8) [37]
and Pindel (v0.2.5) [38]. To generate high confidence
mutation callings, we used the mutations that supported at
least 2 callers, cutoffs of at least 14 total reads in the tumor
and at least 8 in the normal. The mutation list was further
filtered by removing variant alleles observed in fewer than
4 reads, present at a variant allele frequency (VAF) less
than 0.05 in tumor or higher than 0.01 VAF in the normal.
For the candidate somatic mutations, we further filtered
low quality mutations by bam-readcount (-q 10 -b 20)
(https://github.com/genome/bam-readcount).

Statistics
All other comparisons between more than two
groups was done using Kruskal-Wallis test followed by
Dunn’s multiple comparison’s test. Differences were
determined to be significant when p-value < 0.05.

Bulk RNA-seq methods
Transcript quantification was performed using
kallisto (v0.44.0) [26], against the GENCODE transcript
reference (release 29, GRCh38). Subsequent analysis was
performed using R (v3.6.0) and R package ‘tximport’
(v1.12.0) [39] was used to import and aggregate transcript
level data to the gene-level. From the transcripts per
www.oncotarget.com
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